In 7 postoperative gastric cancer patients, the influence of fat emulsi fication of N1 (2-tetrahydrofuryl) -5-fluorouracil (FT-207) on lymphatic trans port was investigated.
ABSTRACT In 7 postoperative gastric cancer patients, the influence of fat emulsi fication of N1 (2-tetrahydrofuryl)
-5-fluorouracil (FT-207) on lymphatic trans port was investigated.
The water in oil type of emulsion of and enteric coated preparation (FT-G) in 1 gram each calculated in terms of FT-207 were ad ministered orally, and lymph from the thoracic duct fistula prepared in ad vance and blood from peripheral vein were collected simultaneously with time after the administration to determine the concentrations of FT-207 and 5-fluorouracil. The subjects were 7 cases of gastric cancer on which radical gastrectomy was performed. All were male, their ages ranging from 34 to 67 and averaging 53.
The emulsion of FT-207 was prepared in accordance with the method of Nakamoto et at.7
Briefly, FT-w/o was prepared by adding 1 gram of FT-207 in 20 ml of water, 0.33 g of hydrogenated caster oil (HCO-60, Nikko Kagaku, Tokyo, Japan) and 1.38 g of sorbitan sesquioleate (SO-15, Nikko Kagaku, Tokyo, Japan) to 30 ml of sesame oil and subjecting the mixture to the ultrasonic treatment in an ultra sonic emulsifier (Model US-600, Nihon Seiki, Tokyo, Japan) at 60°C for 1-2 minutes. was administered as a single oral dose of 1,000 mg. The thoracic duct fistula was made to collect lymph as follows : after applying topical anesthesia to fovea superior of the left cravicle, incision was made along the upper margin of the clavicle to separate the cervical muscle. Adipose tissue located at the cranial to the subclavicular vein, ventral to the anterior scalenus muscle and around the internal jugular vein was removed with Virchow lymph node for histopathological examination. While raising the internal jugular vein, the junction with the subclavicular vein was detached posteriorly to expose the thoracic duct entering the bifurcation of the jugular and subclavicular vein. The thoracic duct was raised with silk sutures and detached from the surrounding tissue after that, a multi-purpose tube was inserted to use as the thoracic duct fistula. After collecting lymph from the thoracic duct fistula, heparin was injected into the multi-purpose tube which was then closed with a cap.
Concentration of FT-207 and its active substance 5-FU was determined as illustrated in Fig. 1 .10 FT-207 was measured by high pressure liquid chromato graphy (HPLC method) and 5-FU by gas chromatography-mass fragmentgraphy (CG-MP method). As for the difference in 5-FU concentration according to the drug form, FT-w/o showed significantly high 5-FU concentration 30-240 minutes after ad ministration in thoracic duct lymph and 30-280 minutes after administration in plasma compared with FT-G (Fig. 3) . No significant differences in the concentration ratios of 5-FU and was observed in the these drugs. Table 2 5-FU concentration in thoracic duct lymph and plasma after administration of FT-207. FT207 was administered as a single oral dose of 1,000 mg
plasma is illustrated in Fig. 4 lymph.13,14 Therefore, the fact that 5-FU concentration in thoracic duct lymph maintained the value of 0.06 ƒÊg/ml or more for 30-480 minutes after administra tion of FT-w/o suggests that FT-w/o can be used as a very useful emulsion in the adjuvant chemotherapy for cancerous tissues remaining in the regional lymph node or lymph tissue in the residual stomach wall after operation for gastric cancer.
FT-w/o shows good absorption probably because this type of emulsion is easily converted to water in oil in water type emulsion in which FT-207 is con tained in the innermost layer in intestinal fluid.
In order to carry out the effective anti-cancer therapy with few side effects, it is desirable to keep the concentration of anti-cancer drugs in plasma at low levels. According to our results , however, It showed low value of 0.5% or less in any drug form.
